CN112708671A - KIR2DS3 genotyping kit and genotyping method - Google Patents
KIR2DS3 genotyping kit and genotyping method Download PDFInfo
- Publication number
- CN112708671A CN112708671A CN202110198853.0A CN202110198853A CN112708671A CN 112708671 A CN112708671 A CN 112708671A CN 202110198853 A CN202110198853 A CN 202110198853A CN 112708671 A CN112708671 A CN 112708671A
- Authority
- CN
- China
- Prior art keywords
- primer
- seq
- nucleotide sequence
- sequencing
- sequencing primer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000003205 genotyping method Methods 0.000 title claims abstract description 27
- 101000945343 Homo sapiens Killer cell immunoglobulin-like receptor 2DS3 Proteins 0.000 title claims abstract description 18
- 102100033625 Killer cell immunoglobulin-like receptor 2DS3 Human genes 0.000 title claims abstract description 17
- 238000012163 sequencing technique Methods 0.000 claims abstract description 270
- 230000003321 amplification Effects 0.000 claims abstract description 153
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 153
- 238000012408 PCR amplification Methods 0.000 claims abstract description 16
- 239000002773 nucleotide Substances 0.000 claims description 121
- 125000003729 nucleotide group Chemical group 0.000 claims description 121
- 108020004414 DNA Proteins 0.000 claims description 30
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 101150056326 KIR2DS3 gene Proteins 0.000 abstract description 16
- 238000000034 method Methods 0.000 abstract description 11
- 108700028369 Alleles Proteins 0.000 abstract description 4
- 239000000047 product Substances 0.000 description 25
- 230000015572 biosynthetic process Effects 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 20
- 238000003786 synthesis reaction Methods 0.000 description 20
- 239000000523 sample Substances 0.000 description 16
- 108010043610 KIR Receptors Proteins 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 102000002698 KIR Receptors Human genes 0.000 description 12
- 238000011144 upstream manufacturing Methods 0.000 description 11
- 210000000822 natural killer cell Anatomy 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 108700024394 Exon Proteins 0.000 description 3
- 239000002250 absorbent Substances 0.000 description 3
- 230000002745 absorbent Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000878007 Miscanthus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a KIR2DS3 genotyping kit and a genotyping method, wherein the KIR2DS3 genotyping kit comprises a first amplification primer, a second amplification primer, a third amplification primer, a fourth amplification primer, a fifth amplification primer, a sixth amplification primer, a first sequencing primer, a second sequencing primer, a third sequencing primer, a fourth sequencing primer, a fifth sequencing primer, a sixth sequencing primer, a seventh sequencing primer, an eighth sequencing primer, a ninth sequencing primer, a tenth sequencing primer, an eleventh sequencing primer, a twelfth sequencing primer, a thirteenth sequencing primer and a fourteenth sequencing primer. According to the invention, the KIR2DS3 gene is subjected to PCR amplification through multiple amplification primers, and the amplified PCR product is subjected to sequencing amplification through multiple sequencing primers, so that the sequencing amplification product is sequenced, a new allele type which is difficult to identify by other methods is found, and high-resolution typing of the KIR2DS3 gene is realized.
Description
Technical Field
The invention relates to the technical field of biology, in particular to a KIR2DS3 genotyping kit and a genotyping method.
Background
Natural Killer cells (NK cells) play an important role in innate and adaptive immunity by acting as cytokines and cytotoxic agents in the human body to combat infection and kill malignant cells. Killer cell Immunoglobulin-like receptors (kirers) are a group of Immunoglobulin-like superfamily members that are mainly expressed on the surface of NK cells and partial T cells, and are capable of specifically recognizing Human major histocompatibility complex MHC-class I molecules (Human leukcyte Antigen I, HLA-I), mediating and regulating the killing function of NK cells and partial effector T cells. An increasing number of clinical transplantation and animal experimental evidence suggests that NK cell allogenic responses triggered by KIR incompatibility in donor and recipient are beneficial for the prognosis of allogeneic hematopoietic stem cell transplantation and organ transplantation. The heterogenous reactive NK cells can specifically kill Host antigen presenting cells and leukemia cells, so that the risk of Graft-Versus-Host Disease (GVHD) is reduced, rejection is relieved, and the effect of Graft-Versus-leukemia is achieved. In addition, KIR has relevance to numerous diseases, including autoimmune diseases, viral infection diseases, tumors, pregnancy-related diseases, and the like.
The KIR gene is located on chromosome 19q13.4 and has high polymorphism, and 14 KIR functional genes and 2 pseudogenes are detected at present. By 12 months 2019, 1110 alleles have been found. The killer cell immunoglobulin-like receptor KIR2DS3 gene is a member of KIR gene family, and has 9 exons, wherein, the 3 rd exon is a false exon.
With the development of transplantation immunity research, the scheme of HLA semi-compatible transplantation is popularized, and how to choose the optimal donor from a plurality of donors becomes a difficult problem for clinical experts. Under the situation, KIR genotyping is paid more and more attention by clinical experts, and the continuous development of detection technology also leads to the trend of high-resolution genotyping. KIR typing methods include sequence-specific primer PCR (PCR-SSP), reverse transcription PCR (RT-PCR), PCR-sequence-specific oligonucleotide probe (PCR-SSO), and the like. However, the above-mentioned various detection methods cannot achieve high-resolution typing of KIR2DS3 gene.
The above is only for the purpose of assisting understanding of the technical solutions of the present invention, and does not represent an admission that the above is the prior art.
Disclosure of Invention
The invention mainly aims to provide a KIR2DS3 genotyping kit, aiming at realizing high-resolution genotyping of KIR2DS3 genes.
In order to achieve the above object, the present invention provides, in a first aspect, a KIR2DS3 genotyping kit, comprising:
the nucleotide sequence of the amplification primer I is shown as SEQ ID No. 1;
the nucleotide sequence of the amplification primer II is shown as SEQ ID No. 2;
the third amplification primer has a nucleotide sequence shown as SEQ ID No. 3;
the fourth amplification primer, the nucleotide sequence of which is shown as SEQ ID No. 4;
the amplification primer V has a nucleotide sequence shown as SEQ ID No. 5;
the sixth amplification primer, the nucleotide sequence of which is shown as SEQ ID No. 6;
the nucleotide sequence of the sequencing primer I is shown as SEQ ID No. 7;
a sequencing primer II, the nucleotide sequence of which is shown as SEQ ID No. 8;
a sequencing primer III, the nucleotide sequence of which is shown as SEQ ID No. 9;
a sequencing primer IV, wherein the nucleotide sequence is shown as SEQ ID No. 10;
a sequencing primer V, the nucleotide sequence of which is shown as SEQ ID No. 11;
a sequencing primer six, the nucleotide sequence of which is shown as SEQ ID No. 12;
a sequencing primer seven, the nucleotide sequence of which is shown as SEQ ID No. 13;
a sequencing primer eight, the nucleotide sequence of which is shown as SEQ ID No. 14;
a ninth sequencing primer, the nucleotide sequence of which is shown as SEQ ID No. 15;
a sequencing primer ten, the nucleotide sequence of which is shown as SEQ ID No. 16;
the eleven sequencing primers have nucleotide sequences shown as SEQ ID No. 17;
a twelve sequencing primer, the nucleotide sequence of which is shown as SEQ ID No. 18;
thirteen sequencing primers, wherein the nucleotide sequence is shown as SEQ ID No. 19; and
and the sequencing primer is fourteen, and the nucleotide sequence is shown as SEQ ID No. 20.
In a second aspect, the invention provides a KIR2DS3 genotyping method, which comprises the following steps:
(1) obtaining the genome DNA of a sample to be detected;
(2) performing PCR amplification by using the first amplification primer, the second amplification primer, the third amplification primer, the fourth amplification primer, the fifth amplification primer and the sixth amplification primer respectively by taking the genomic DNA as a template to obtain corresponding amplification products;
(3) amplifying the corresponding amplification products respectively by utilizing a first sequencing primer, a second sequencing primer, a third sequencing primer, a fourth sequencing primer, a fifth sequencing primer, a sixth sequencing primer, a seventh sequencing primer, an eighth sequencing primer, a ninth sequencing primer, a tenth sequencing primer, an eleventh sequencing primer, a twelfth sequencing primer, a thirteenth sequencing primer and a fourteenth sequencing primer to obtain corresponding sequencing amplification products;
(4) sequencing the sequencing amplification product, analyzing SNP locus information in a nucleotide sequence, and comparing the SNP locus information with a public database to obtain the genotyping of KIR2DS 3;
wherein, the nucleotide sequence of the first amplification primer is shown as SEQ ID No.1, the nucleotide sequence of the second amplification primer is shown as SEQ ID No.2, the nucleotide sequence of the third amplification primer is shown as SEQ ID No.3, the nucleotide sequence of the fourth amplification primer is shown as SEQ ID No.4, the nucleotide sequence of the fifth amplification primer is shown as SEQ ID No.5, the nucleotide sequence of the sixth amplification primer is shown as SEQ ID No.6, the nucleotide sequence of the first sequencing primer is shown as SEQ ID No.7, the nucleotide sequence of the second sequencing primer is shown as SEQ ID No.8, the nucleotide sequence of the third sequencing primer is shown as SEQ ID No.9, the nucleotide sequence of the fourth sequencing primer is shown as SEQ ID No.10, the nucleotide sequence of the fifth sequencing primer is shown as SEQ ID No.11, and the nucleotide sequence of the sixth sequencing primer is shown as SEQ ID No.12, the nucleotide sequence of the seventh sequencing primer is shown as SEQ ID No.13, the nucleotide sequence of the eighth sequencing primer is shown as SEQ ID No.14, the nucleotide sequence of the ninth sequencing primer is shown as SEQ ID No.15, the nucleotide sequence of the tenth sequencing primer is shown as SEQ ID No.16, the nucleotide sequence of the eleventh sequencing primer is shown as SEQ ID No.17, the nucleotide sequence of the twelfth sequencing primer is shown as SEQ ID No.18, the nucleotide sequence of the thirteenth sequencing primer is shown as SEQ ID No.19, and the nucleotide sequence of the fourteenth sequencing primer is shown as SEQ ID No. 20.
The KIR2DS3 genotyping kit comprises a first amplification primer, a second amplification primer, a third amplification primer, a fourth amplification primer, a fifth amplification primer, a sixth amplification primer, a first sequencing primer, a second sequencing primer, a third sequencing primer, a fourth sequencing primer, a fifth sequencing primer, a sixth sequencing primer, a seventh sequencing primer, an eighth sequencing primer, a ninth sequencing primer, a tenth sequencing primer, an eleventh sequencing primer, a twelfth sequencing primer, a thirteenth sequencing primer and a fourteenth sequencing primer; the KIR2DS3 gene is subjected to PCR amplification through multiple amplification primers, and the amplified PCR product is subjected to sequencing amplification through multiple sequencing primers, so that the sequencing amplification product is sequenced, a new allele type which is difficult to identify by other methods is found, and high-resolution typing of the KIR2DS3 gene is realized.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to the structures shown in the drawings without creative efforts.
FIG. 1 is an agarose gel electrophoresis of the PCR amplification product of the first embodiment;
FIG. 2 is a diagram showing the result of the 13794 th SNP alignment of example II.
The implementation, functional features and advantages of the objects of the present invention will be further explained with reference to the accompanying drawings.
Detailed Description
It should be noted that if the description of "first", "second", etc. is provided in the embodiment of the present invention, the description of "first", "second", etc. is only for descriptive purposes and is not to be construed as indicating or implying relative importance or implicitly indicating the number of indicated technical features. Thus, a feature defined as "first" or "second" may explicitly or implicitly include at least one such feature. In addition, the meaning of "and/or" appearing throughout is to include three juxtapositions, exemplified by "A and/or B" including either scheme A, or scheme B, or a scheme in which both A and B are satisfied.
The invention provides a KIR2DS3 genotyping kit.
Referring to tables 1 and 2, the KIR2DS3 genotyping kit provided by the invention comprises an amplification primer i, an amplification primer ii, an amplification primer iii, an amplification primer iv, a sequencing primer i, a sequencing primer ii, a sequencing primer iii, a sequencing primer iv, a sequencing primer thirteen, and a sequencing primer fourteen; wherein, the nucleotide sequence of the first amplification primer is shown as SEQ ID No.1, the nucleotide sequence of the second amplification primer is shown as SEQ ID No.2, the nucleotide sequence of the third amplification primer is shown as SEQ ID No.3, the nucleotide sequence of the fourth amplification primer is shown as SEQ ID No.4, the nucleotide sequence of the fifth amplification primer is shown as SEQ ID No.5, the nucleotide sequence of the sixth amplification primer is shown as SEQ ID No.6, the nucleotide sequence of the first sequencing primer is shown as SEQ ID No.7, the nucleotide sequence of the second sequencing primer is shown as SEQ ID No.8, the nucleotide sequence of the third sequencing primer is shown as SEQ ID No.9, the nucleotide sequence of the fourth sequencing primer is shown as SEQ ID No.10, the nucleotide sequence of the fifth sequencing primer is shown as SEQ ID No.11, and the nucleotide sequence of the sixth sequencing primer is shown as SEQ ID No.12, the nucleotide sequence of the seventh sequencing primer is shown as SEQ ID No.13, the nucleotide sequence of the eighth sequencing primer is shown as SEQ ID No.14, the nucleotide sequence of the ninth sequencing primer is shown as SEQ ID No.15, the nucleotide sequence of the tenth sequencing primer is shown as SEQ ID No.16, the nucleotide sequence of the eleventh sequencing primer is shown as SEQ ID No.17, the nucleotide sequence of the twelfth sequencing primer is shown as SEQ ID No.18, the nucleotide sequence of the thirteenth sequencing primer is shown as SEQ ID No.19, and the nucleotide sequence of the fourteenth sequencing primer is shown as SEQ ID No. 20.
Referring to table 1, the first amplification primer is an amplification upstream primer, the second amplification primer is an amplification downstream primer, and the first amplification primer and the second amplification primer specifically amplify a sequence of a 5' UTR region, a 1 st exon, a 1 st intron, a 2 nd exon, a 2 nd intron, a 3 rd exon (pseudo exon), a 3 rd intron, a 4 th exon, a 4 th intron, a 5 th exon and a part of a 5 th intron of a KIR2DS3 gene, which is named as P1; the third amplification primer is an amplification upstream primer, the fourth amplification primer is an amplification downstream primer, and the third amplification primer and the fourth amplification primer specifically amplify the sequences of a part of the 5 th intron, a part of the 6 th exon and a part of the 6 th intron of the KIR2DS3 gene, wherein the sequence is named as P2; the fifth amplification primer is an amplification upstream primer, the sixth amplification primer is an amplification downstream primer, and the fifth amplification primer and the sixth amplification primer specifically amplify sequences of a part of 6 th intron, 7 th exon, 7 th intron, 8 th exon, 8 th intron, 9 th exon and a part of 3' end UTR region of the KIR2DS3 gene, wherein the sequence is named as P3.
The 2DS3 x 0010301 gene obtained from KIR public database (https:// www.ebi.ac.uk/ipd/KIR /) was selected as a control gene and the position of each primer in the genome was aligned. The total length of the control gene covers from 5 'UTR region to 3' UTR region of KIR2DS3 gene, total 15103 bp.
TABLE 1 PCR amplification primer information
The PCR amplification method comprises the following steps of carrying out sequencing amplification on a purified PCR amplification product, wherein the PCR amplification product comprises a sequencing primer I, a sequencing primer II, a sequencing primer III, a sequencing primer IV, a sequencing primer V, a sequencing primer VI, a sequencing primer VII, a sequencing primer nine, a sequencing primer Ten, a sequencing primer eleven, a sequencing primer twelve, a sequencing primer thirteen and a sequencing primer fourteen.
Referring to table 2, the first sequencing primer is an amplification upstream primer, the second sequencing primer is an amplification downstream primer, and the first sequencing primer and the second sequencing primer pair perform sequencing amplification on the exon 1 sequence in P1; the third sequencing primer is an amplification upstream primer, the fourth sequencing primer is an amplification downstream primer, and the third sequencing primer and the fourth sequencing primer perform sequencing amplification on the 2 nd exon sequence in the P1; the sequencing primer five is an amplification upstream primer, the sequencing primer six is an amplification downstream primer, and sequencing amplification is carried out on the exon 4 sequence in the P1 pair by the sequencing primer five and the sequencing primer six; the seventh sequencing primer is an amplification upstream primer, the eighth sequencing primer is an amplification downstream primer, and the seventh sequencing primer and the eighth sequencing primer perform sequencing amplification on the 5 th exon sequence in the P1; the sequencing primer nine is an amplification upstream primer, the sequencing primer ten is an amplification downstream primer, and the sequencing primer nine and the sequencing primer ten carry out sequencing amplification on the 6 th exon sequence in the P2; the eleven sequencing primer is an amplification upstream primer, the twelve sequencing primer is an amplification downstream primer, and the 7 th exon in the twelve pairs of P3 of the eleven sequencing primer and the twelve sequencing primer is subjected to sequencing amplification; the sequencing primer thirteen is an amplification upstream primer, the sequencing primer fourteen is an amplification downstream primer, and the sequencing primer thirteen and the sequencing primer fourteen carry out sequencing amplification on the 8 th exon and the 9 th exon in the P3.
Since exon 3 of KIR2DS3 gene is a pseudo exon, sequencing primers are not designed for exon 3 for sequencing amplification in the present invention.
TABLE 2 sequencing primer information
The invention also provides a KIR2DS3 genotyping method, which comprises the following steps:
(1) obtaining the genome DNA of a sample to be detected; (2) performing PCR amplification by using the first amplification primer, the second amplification primer, the third amplification primer, the fourth amplification primer, the fifth amplification primer and the sixth amplification primer respectively by taking the genomic DNA as a template to obtain corresponding amplification products; (3) amplifying the corresponding amplification products respectively by utilizing a first sequencing primer, a second sequencing primer, a third sequencing primer, a fourth sequencing primer, a fifth sequencing primer, a sixth sequencing primer, a seventh sequencing primer, an eighth sequencing primer, a ninth sequencing primer, a tenth sequencing primer, an eleventh sequencing primer, a twelfth sequencing primer, a thirteenth sequencing primer and a fourteenth sequencing primer to obtain corresponding sequencing amplification products; (4) sequencing the sequencing amplification product, analyzing SNP locus information in a nucleotide sequence, and comparing the SNP locus information with a public database to obtain the genotyping of KIR2DS 3; wherein, the nucleotide sequence of the first amplification primer is shown as SEQ ID No.1, the nucleotide sequence of the second amplification primer is shown as SEQ ID No.2, the nucleotide sequence of the third amplification primer is shown as SEQ ID No.3, the nucleotide sequence of the fourth amplification primer is shown as SEQ ID No.4, the nucleotide sequence of the fifth amplification primer is shown as SEQ ID No.5, the nucleotide sequence of the sixth amplification primer is shown as SEQ ID No.6, the nucleotide sequence of the first sequencing primer is shown as SEQ ID No.7, the nucleotide sequence of the second sequencing primer is shown as SEQ ID No.8, the nucleotide sequence of the third sequencing primer is shown as SEQ ID No.9, the nucleotide sequence of the fourth sequencing primer is shown as SEQ ID No.10, the nucleotide sequence of the fifth sequencing primer is shown as SEQ ID No.11, and the nucleotide sequence of the sixth sequencing primer is shown as SEQ ID No.12, the nucleotide sequence of the seventh sequencing primer is shown as SEQ ID No.13, the nucleotide sequence of the eighth sequencing primer is shown as SEQ ID No.14, the nucleotide sequence of the ninth sequencing primer is shown as SEQ ID No.15, the nucleotide sequence of the tenth sequencing primer is shown as SEQ ID No.16, the nucleotide sequence of the eleventh sequencing primer is shown as SEQ ID No.17, the nucleotide sequence of the twelfth sequencing primer is shown as SEQ ID No.18, the nucleotide sequence of the thirteenth sequencing primer is shown as SEQ ID No.19, and the nucleotide sequence of the fourteenth sequencing primer is shown as SEQ ID No. 20.
The method comprises the following specific steps:
1) PCR amplification
For the amplification primer information, see table 1, for the reaction system, see table 3, and for the reaction conditions, see table 4.
TABLE 3 PCR reaction System
Reagent | Volume of |
Genomic DNA (30 to 200 ng/. mu.l) | 3.0μl |
Vazyme Lamp(5U/μL) | 0.3μl |
Vazyme 5×Enhancer | 5.0μl |
10×PCR buffer | 2.5μl |
dNTP(2.5mM) | 2.0μl |
Upstream primer (10. mu.M) | 1.0μl |
Downstream primer (10. mu.M) | 1.0μl |
ddH2O | Make up to 25.0 mul of total volume |
TABLE 4 PCR reaction procedure
2) PCR product purification
After the PCR amplification is finished, the amplification product is purified, and the interference of the PCR reaction reagent on the subsequent sequencing reaction is avoided. The reaction system for purification of the amplification product is shown in Table 5, and the purification conditions are shown in Table 6.
TABLE 5 amplification product purification System
TABLE 6 amplification product purification conditions
Step (ii) of | Temperature of | |
|
1 | 37 | 90min | |
2 | 80℃ | 15min |
3) Sequencing amplification
And sequencing and amplifying the purified amplification product. For information on sequencing amplification primers, see table 2, for reaction system, see table 7, and for reaction conditions, see table 8.
TABLE 7 sequencing amplification reaction System
Reagent | Volume of |
BigDye Terminator v3.1 | 0.5μl |
5×BigDye Sequencing Buffer | 0.75μl |
Sequencing primer (3.2. mu.M) | 1.0μl |
Purified PCR amplification product | 1.5μl |
ddH2O | Adding to a total volume of 5.0. mu.l |
TABLE 8 sequencing amplification reaction procedure
4) Sequencing amplification product purification
After the sequencing amplification reaction is completed, purifying the sequencing amplification product so as to prevent the sequencing amplification reagent from interfering the sequencing process, and the steps are as follows:
a) reacting absolute ethyl alcohol with ddH2Mixing O, and preparing 85% ethanol and 70% ethanol;
b) after the sequencing reaction plate is centrifuged, 2 mu l of EDTA solution and 40 mu l of 85% ethanol are respectively added into each reaction hole, a silica gel pad is covered on each reaction hole, the mixture is fully vibrated for 3min, and the mixture is centrifuged at 4 ℃ and 3,000 Xg for 30 min;
c) taking out the sequencing reaction plate after the centrifugation is finished, spreading absorbent paper with enough thickness in a centrifugation hanging basket, slightly uncovering a silica gel pad of the sequencing reaction plate, inversely placing the sequencing reaction plate on the absorbent paper, and centrifuging the sequencing reaction plate and the absorbent paper together until the centrifugal force reaches 185 Xg;
d) adding 70% ethanol 50 μ l into each well, covering with silica gel pad, shaking for 2min, centrifuging at 4 deg.C and 3,000 Xg for 15 min;
e) repeating the step c;
f) drying the sequencing reaction plate for 20min in the dark, adding 10 mul of ultrapure formamide into each hole, covering a silica gel pad, performing instantaneous centrifugation, and reacting for 2min at 96 ℃ in a PCR instrument;
g) sequencing the purified sequencing reaction product by using an ABI3730xl sequencer;
h) and (3) comparing a sequencing sequence file generated by a sequencer with a 2DS3 x 0010301 reference sequence by using SnapGene software (https:// www.snapgene.com), generating corresponding SNP and position information thereof, and comparing with a KIR public database to obtain a high-resolution type of the KIR2DS3 gene.
The KIR2DS3 genotyping kit comprises a first amplification primer, a second amplification primer, a third amplification primer, a fourth amplification primer, a fifth amplification primer, a sixth amplification primer, a first sequencing primer, a second sequencing primer, a third sequencing primer, a fourth sequencing primer, a fifth sequencing primer, a sixth sequencing primer, a seventh sequencing primer, an eighth sequencing primer, a ninth sequencing primer, a tenth sequencing primer, an eleventh sequencing primer, a twelfth sequencing primer, a thirteenth sequencing primer and a fourteenth sequencing primer; the KIR2DS3 gene is subjected to PCR amplification through multiple amplification primers, and the amplified PCR product is subjected to sequencing amplification through multiple sequencing primers, so that the sequencing amplification product is sequenced, a new allele type which is difficult to identify by other methods is found, and high-resolution typing of the KIR2DS3 gene is realized.
Example one
Two positive samples subjected to KIR2DS3 gene low-resolution typing are randomly selected, and KIR2DS3 gene typing is carried out on the samples by adopting the kit and the typing method so as to verify the typing effect of the invention. Extracting the genome DNA of the sample, and carrying out PCR amplification on the genome DNA. The results of PCR amplification are shown in FIG. 1. In FIG. 1, the bands of the agarose gel electrophoresis image are, from left to right, DL15000 DNA Marker, P1 sequence of sample (i), P1 sequence of sample (ii), P2 sequence of sample (i), P2 sequence of sample (ii), P3 sequence of sample (i) and P3 sequence of sample (ii). The sequence length of P1 is 6388bp, the sequence length of P2 is 1543bp, the sequence length of P3 is 3495bp, the results in the figure are consistent with the reality, which shows that the sequences are successfully amplified.
Sequencing the purified sequencing amplification product to obtain 14 sequencing peak maps. The 14 sequencing peaks were each introduced into SnapGene software, and aligned With the Sequence of 2DS3 × 0010301 using the "Align With a Sequence Trace" function of the SnapGene software.
The alignment results showed that no SNPs were found in samples relative to the reference sequence 2DS3 × 0010301, i.e. the sequences in exons 1, 2, 4, 5, 6, 7, 8 and 9 were identical to the reference sequence 2DS3 × 0010301.
Referring to FIG. 2, the alignment shows that sample (C) has 1 SNP in the 13794 th exon relative to the 2DS3 x 0010301 reference sequence, sample (C) has A base at this position (marked by a black box), and 2DS3 x 0010301 reference sequence has G base at this position. Sample 2, the sequences of exons 1, 2, 4, 5, 6, 8 and 9 were completely identical to 2DS3 × 0010301, and no other SNPs were found.
In this example, the SNP result obtained by alignment in sample i is consistent with the reference sequence, so the high resolution typing result of sample i KIR2DS3 is 2DS3 × 00103 homozygote. Querying a KIR public database to find that the SNP result obtained by comparing the sample (2) is consistent with 2DS3 × 00201, and the high-resolution typing result of the sample (KIR 2DS 3) is 2DS3 × 00201 homozygote. The above results demonstrate that the kit and typing method of the present invention can achieve high resolution typing of KIR2DS 3.
The above description is only a preferred embodiment of the present invention, and is not intended to limit the scope of the present invention, and all modifications and equivalents of the present invention, which are made by the contents of the present specification and the accompanying drawings, or directly/indirectly applied to other related technical fields, are included in the scope of the present invention.
SEQUENCE LISTING
<110> Shenzhen silvergrass Beiken precision medicine Limited
SHANGHAI TISSUEBANK MEDICAL INSPECTION Co.,Ltd.
SHANGHAI TISSUEBANK BIOTECHNOLOGY Co.,Ltd.
Shanghai Yushuo Beiken Gene Technology Co., Ltd.
<120> KIR2DS3 genotyping kit and genotyping method
<130>
<160> 20
<170> PatentIn version 3.3
<210> 1
<211> 28
<212> DNA
<213> Artificial Synthesis
<400> 1
agcacagatt ttaggcatcc tgtgtacc 28
<210> 2
<211> 22
<212> DNA
<213> Artificial Synthesis
<400> 2
agggtttgga ggtgccctat cg 22
<210> 3
<211> 29
<212> DNA
<213> Artificial Synthesis
<400> 3
acgtcctgga gcatttcccc aatattact 29
<210> 4
<211> 29
<212> DNA
<213> Artificial Synthesis
<400> 4
gcacttcata ctttgagcta cagcactgc 29
<210> 5
<211> 25
<212> DNA
<213> Artificial Synthesis
<400> 5
ccacacacag ctctcagccg tgaac 25
<210> 6
<211> 26
<212> DNA
<213> Artificial Synthesis
<400> 6
ctgtggtgct cgtggacaga agactg 26
<210> 7
<211> 18
<212> DNA
<213> Artificial Synthesis
<400> 7
ccgtgttctg ctcttgag 18
<210> 8
<211> 18
<212> DNA
<213> Artificial Synthesis
<400> 8
gcctatatct ccacctct 18
<210> 9
<211> 20
<212> DNA
<213> Artificial Synthesis
<400> 9
gcctggctac caagactcac 20
<210> 10
<211> 17
<212> DNA
<213> Artificial Synthesis
<400> 10
gcgaggtcgg aactgtg 17
<210> 11
<211> 19
<212> DNA
<213> Artificial Synthesis
<400> 11
agcctcactc aatccaggt 19
<210> 12
<211> 19
<212> DNA
<213> Artificial Synthesis
<400> 12
tcttccttac aaccacctg 19
<210> 13
<211> 19
<212> DNA
<213> Artificial Synthesis
<400> 13
gagcagggga gtgagttct 19
<210> 14
<211> 20
<212> DNA
<213> Artificial Synthesis
<400> 14
ctcagcagga agctcctcag 20
<210> 15
<211> 18
<212> DNA
<213> Artificial Synthesis
<400> 15
acagtgggcg tcacatac 18
<210> 16
<211> 18
<212> DNA
<213> Artificial Synthesis
<400> 16
tcactgagcc ctgtgttg 18
<210> 17
<211> 21
<212> DNA
<213> Artificial Synthesis
<400> 17
cgttgtatgt ggttacctgt c 21
<210> 18
<211> 17
<212> DNA
<213> Artificial Synthesis
<400> 18
cagggaccat cctgcct 17
<210> 19
<211> 18
<212> DNA
<213> Artificial Synthesis
<400> 19
atgggatggg tccttgag 18
<210> 20
<211> 19
<212> DNA
<213> Artificial Synthesis
<400> 20
gctttggatc tggactcag 19
Claims (2)
1. A KIR2DS3 genotyping kit, comprising:
the nucleotide sequence of the amplification primer I is shown as SEQ ID No. 1;
the nucleotide sequence of the amplification primer II is shown as SEQ ID No. 2;
the third amplification primer has a nucleotide sequence shown as SEQ ID No. 3;
the fourth amplification primer, the nucleotide sequence of which is shown as SEQ ID No. 4;
the amplification primer V has a nucleotide sequence shown as SEQ ID No. 5;
the sixth amplification primer, the nucleotide sequence of which is shown as SEQ ID No. 6;
the nucleotide sequence of the sequencing primer I is shown as SEQ ID No. 7;
a sequencing primer II, the nucleotide sequence of which is shown as SEQ ID No. 8;
a sequencing primer III, the nucleotide sequence of which is shown as SEQ ID No. 9;
a sequencing primer IV, wherein the nucleotide sequence is shown as SEQ ID No. 10;
a sequencing primer V, the nucleotide sequence of which is shown as SEQ ID No. 11;
a sequencing primer six, the nucleotide sequence of which is shown as SEQ ID No. 12;
a sequencing primer seven, the nucleotide sequence of which is shown as SEQ ID No. 13;
a sequencing primer eight, the nucleotide sequence of which is shown as SEQ ID No. 14;
a ninth sequencing primer, the nucleotide sequence of which is shown as SEQ ID No. 15;
a sequencing primer ten, the nucleotide sequence of which is shown as SEQ ID No. 16;
the eleven sequencing primers have nucleotide sequences shown as SEQ ID No. 17;
a twelve sequencing primer, the nucleotide sequence of which is shown as SEQ ID No. 18;
thirteen sequencing primers, wherein the nucleotide sequence is shown as SEQ ID No. 19; and
and the sequencing primer is fourteen, and the nucleotide sequence is shown as SEQ ID No. 20.
2. A KIR2DS3 genotyping method is characterized by comprising the following steps:
(1) obtaining the genome DNA of a sample to be detected;
(2) performing PCR amplification by using the first amplification primer, the second amplification primer, the third amplification primer, the fourth amplification primer, the fifth amplification primer and the sixth amplification primer respectively by taking the genomic DNA as a template to obtain corresponding amplification products;
(3) amplifying the corresponding amplification products respectively by utilizing a first sequencing primer, a second sequencing primer, a third sequencing primer, a fourth sequencing primer, a fifth sequencing primer, a sixth sequencing primer, a seventh sequencing primer, an eighth sequencing primer, a ninth sequencing primer, a tenth sequencing primer, an eleventh sequencing primer, a twelfth sequencing primer, a thirteenth sequencing primer and a fourteenth sequencing primer to obtain corresponding sequencing amplification products;
(4) sequencing the sequencing amplification product, analyzing SNP locus information in a nucleotide sequence, and comparing the SNP locus information with a public database to obtain the genotyping of KIR2DS 3;
wherein, the nucleotide sequence of the first amplification primer is shown as SEQ ID No.1, the nucleotide sequence of the second amplification primer is shown as SEQ ID No.2, the nucleotide sequence of the third amplification primer is shown as SEQ ID No.3, the nucleotide sequence of the fourth amplification primer is shown as SEQ ID No.4, the nucleotide sequence of the fifth amplification primer is shown as SEQ ID No.5, the nucleotide sequence of the sixth amplification primer is shown as SEQ ID No.6, the nucleotide sequence of the first sequencing primer is shown as SEQ ID No.7, the nucleotide sequence of the second sequencing primer is shown as SEQ ID No.8, the nucleotide sequence of the third sequencing primer is shown as SEQ ID No.9, the nucleotide sequence of the fourth sequencing primer is shown as SEQ ID No.10, the nucleotide sequence of the fifth sequencing primer is shown as SEQ ID No.11, and the nucleotide sequence of the sixth sequencing primer is shown as SEQ ID No.12, the nucleotide sequence of the seventh sequencing primer is shown as SEQ ID No.13, the nucleotide sequence of the eighth sequencing primer is shown as SEQ ID No.14, the nucleotide sequence of the ninth sequencing primer is shown as SEQ ID No.15, the nucleotide sequence of the tenth sequencing primer is shown as SEQ ID No.16, the nucleotide sequence of the eleventh sequencing primer is shown as SEQ ID No.17, the nucleotide sequence of the twelfth sequencing primer is shown as SEQ ID No.18, the nucleotide sequence of the thirteenth sequencing primer is shown as SEQ ID No.19, and the nucleotide sequence of the fourteenth sequencing primer is shown as SEQ ID No. 20.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110198853.0A CN112708671A (en) | 2021-02-22 | 2021-02-22 | KIR2DS3 genotyping kit and genotyping method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110198853.0A CN112708671A (en) | 2021-02-22 | 2021-02-22 | KIR2DS3 genotyping kit and genotyping method |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112708671A true CN112708671A (en) | 2021-04-27 |
Family
ID=75550208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110198853.0A Pending CN112708671A (en) | 2021-02-22 | 2021-02-22 | KIR2DS3 genotyping kit and genotyping method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112708671A (en) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080213787A1 (en) * | 2005-09-29 | 2008-09-04 | Trachtenberg Elizabeth A | Methods and Compositions for Kir Genotyping |
US20120122719A1 (en) * | 2009-11-16 | 2012-05-17 | Hogan Michael E | Methods for PCR and HLA typing using unpurified samples |
CN104032025A (en) * | 2014-06-25 | 2014-09-10 | 上海荻硕贝肯生物科技有限公司 | Primers, kit and method for quickly typing KIR (Killer Immunoglobulin-like Receptor) genes |
CN106222288A (en) * | 2016-08-15 | 2016-12-14 | 中国医学科学院输血研究所 | Primer combination and test kit and method for the detection of KIR gene PCR SSP typing |
CN107058544A (en) * | 2017-04-25 | 2017-08-18 | 深圳市血液中心 | The method of the synchronous sequencing and typing of 14 feature killer cell immunoglobulin-like receptors KIRs genes |
CN109715829A (en) * | 2016-05-16 | 2019-05-03 | 迪莫·迪特里希 | A method of the reaction of assessment prognosis and prediction malignant disease patient to immunization therapy |
CN110331193A (en) * | 2019-07-14 | 2019-10-15 | 浙江省血液中心 | A kind of mankind kill the PCR-SBT method and reagent of cell immunoglobulin receptor KIR3DL2 Genotyping |
-
2021
- 2021-02-22 CN CN202110198853.0A patent/CN112708671A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080213787A1 (en) * | 2005-09-29 | 2008-09-04 | Trachtenberg Elizabeth A | Methods and Compositions for Kir Genotyping |
US20120122719A1 (en) * | 2009-11-16 | 2012-05-17 | Hogan Michael E | Methods for PCR and HLA typing using unpurified samples |
CN104032025A (en) * | 2014-06-25 | 2014-09-10 | 上海荻硕贝肯生物科技有限公司 | Primers, kit and method for quickly typing KIR (Killer Immunoglobulin-like Receptor) genes |
CN109715829A (en) * | 2016-05-16 | 2019-05-03 | 迪莫·迪特里希 | A method of the reaction of assessment prognosis and prediction malignant disease patient to immunization therapy |
CN106222288A (en) * | 2016-08-15 | 2016-12-14 | 中国医学科学院输血研究所 | Primer combination and test kit and method for the detection of KIR gene PCR SSP typing |
CN107058544A (en) * | 2017-04-25 | 2017-08-18 | 深圳市血液中心 | The method of the synchronous sequencing and typing of 14 feature killer cell immunoglobulin-like receptors KIRs genes |
CN110331193A (en) * | 2019-07-14 | 2019-10-15 | 浙江省血液中心 | A kind of mankind kill the PCR-SBT method and reagent of cell immunoglobulin receptor KIR3DL2 Genotyping |
Non-Patent Citations (7)
Title |
---|
H. A. HONG ET AL: "Killer-cell immunoglobulin-like receptor genotyping and HLA killer-cell immunoglobulin-like receptor-ligand identification by real-time polymerase chain reaction", 《TISSUE ANTIGENS》, vol. 78, no. 03, 2 August 2011 (2011-08-02), pages 188 - 189 * |
HONG-DAN WANG ET AL: "Genetic polymorphism analysis of killer cell immunoglobulin-like receptor genes in the Chinese Uygur population", 《MOL BIOL REP》, vol. 39, no. 03, 31 March 2012 (2012-03-31), pages 3019 * |
JOHANNES SCHETELIG ET AL: "External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails", 《BLOOD》, vol. 135, no. 16, 16 April 2020 (2020-04-16), pages 1387 * |
SHAGHIK BARANI ET AL: "KIR2DS1, 2DS5, 3DS1 and KIR2DL5 are associated with the risk of head and neck squamous cell carcinoma in Iranians", 《HUMAN IMMUNOLOGY》, vol. 79, no. 04, 9 February 2018 (2018-02-09), pages 2, XP085378497, DOI: 10.1016/j.humimm.2018.01.012 * |
于浩 等: "《生物信息学实验指导》", 30 September 2009, 吉林大学出版社, pages: 124 - 127 * |
胡丽华主编: "《检验 输血 病理诊疗常规》", 31 May 2006, 湖北科学技术出版社, pages: 622 - 623 * |
陈士华等: "杀伤细胞免疫球蛋白样受体基因分型技术的研究进展", 《中国生物制品学杂志》, no. 03, 20 March 2008 (2008-03-20), pages 244 - 247 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Costa et al. | Mitochondrial DNA sequence analysis of a native Bolivian population | |
CN109385482B (en) | SNP molecular marker related to lefteye flounder fertility and screening method and application thereof | |
CN112226505A (en) | Respiratory system disease gene SNP locus typing optimization method | |
Noda et al. | Mitochondrial 16S rRNA sequence diversity of hominoids | |
CN112708671A (en) | KIR2DS3 genotyping kit and genotyping method | |
Hou et al. | Thirty allele-level haplotypes centered around KIR2DL5 define the diversity in an African American population | |
CN112746099A (en) | KIR2DS4 genotyping kit and genotyping method | |
CN112852939A (en) | KIR2DL1 genotyping kit and genotyping method | |
CN112852940A (en) | KIR2DS2 genotyping kit and genotyping method | |
CN107937487B (en) | It is a kind of for the amplification of HLA-A gene PCR, the method for Genotyping, primer sets and kit | |
CN112708672A (en) | KIR2DS5 genotyping kit and genotyping method | |
CN112708667A (en) | KIR3DS1 genotyping kit and genotyping method | |
CN112725428A (en) | KIR2DL4 genotyping kit and genotyping method | |
CN112852932A (en) | KIR3DL3 genotyping kit and genotyping method | |
CN112725442A (en) | KIR3DL2 genotyping kit and genotyping method | |
CN112725441A (en) | KIR2DS1 genotyping kit and genotyping method | |
CN112725421A (en) | KIR3DL1 genotyping kit and genotyping method | |
CN112725420A (en) | KIR2DL5 genotyping kit and genotyping method | |
CN112746098A (en) | KIR2DL2 genotyping kit and genotyping method | |
CN112831553A (en) | KIR2DL3 genotyping kit and genotyping method | |
Iwasa et al. | Genetic variation at five STR loci in subpopulations living in Turkey | |
CN114854737A (en) | Class I HLA gene amplification primer, kit and typing method based on third-generation sequencing platform | |
CN111500735B (en) | Primer group, probe and kit for direct amplification and detection of high-incidence tumor susceptibility gene polymorphism without taking hands, and method thereof | |
CN109022594B (en) | Cattle AHSG gene SNP marker related to conversion efficiency of beef cattle feed | |
CN106119244A (en) | The test kit of detection Kui sulfur flat medication effect based on rs6269 and using method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210427 |
|
RJ01 | Rejection of invention patent application after publication |